Podcast appearances and mentions of Michael G Ison

Effective influenza management during the COVID-19 pandemic requires a knowledge of emerging diagnostics, immunizations, and antiviral agents. The armamentarium for influenza treatment now includes multiple classes including neuraminidase inhibitors (eg, oseltamivir) and the polymerase acidic endonuclease inhibitor, baloxavir. In this podcast, Mary Knudtson, DNSc, NP, FAAN, asks questions from healthcare professionals to infectious disease expert, Michael G. Ison, MD, MS on timely, individualized influenza prevention and treatment. This activity is available for CE/CME credit. Claim your credit at pce.is/flu.

Dr. Michael G. Ison discusses our current knowledge of COVID-19 treatment for both ambulatory and hospitalized patients and answers your COVID-19 questions. Topics: *Methods to improve outpatient management of COVID-19 patients *Individualizing treatment for hospitalized patients *Gaps in our understanding and investigational treatments *Clinical trial data of currently authorized or approved treatments and in-development therapeutics Post-test for CME/CE credit: https://covid19.dkbmed.com/#eval-test-1-27Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/Presenting faculty: Michael G. Ison, MD MS FIDSA FAST, Professor, Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine See acast.com/privacy for privacy and opt-out information.

Dr. Michael G. Ison, Professor of Divisions of Infectious Diseases and Organ Transplantation, discusses our fundamental understanding of COVID-19 vaccines. Topics: *How mRNA, RNA/DNA, and protein vaccines work *Latest data on vaccine efficacy *What to know about vaccine rollout *Estimated time to herd immunityPost-test for CME/CE credit: https://covid19.dkbmed.com/#eval-test-1-20Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/Presenting faculty: Michael G. Ison, MD MS FIDSA FAST, Professor, Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine See acast.com/privacy for privacy and opt-out information.

Dr. Paul Auwaerter interviews Dr. Michael G. Ison, Professor of Divisions of Infectious Diseases and Organ Transplantation, about his experience treating COVID-19. Topics: *How COVID-19 impacted influenza in the Southern Hemisphere *Distinguishing influenza from COVID-19 *Changes to testing procedures for the flu season *Potential benefits of expanding antiviral use for influenza *The future of influenza … Continue reading "UPDATE 10/07/2020 – COVID-19 Infectious Disease Expert Interview" The post UPDATE 10/07/2020 – COVID-19 Infectious Disease Expert Interview appeared first on DKBmed Radio.

Dr. Paul Auwaerter interviews Dr. Michael G. Ison, Professor of Divisions of Infectious Diseases and Organ Transplantation, about his experience treating COVID-19. Topics: *Impact of COVID-19 in the Midwest region *How behavior impacts spread of infectious disease *Expectations of COVID-19 in the future *Gold standard of COVID-19 testing *Therapeutic procedures at Northwestern The post UPDATE 9/30/2020 – COVID-19 Infectious Disease Expert Interview appeared first on DKBmed Radio.

Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.

Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.

Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.

Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.

Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.

Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.

Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.

Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.

Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.

Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.